4.6 Review

Therapeutic potential of interleukin-2 in autoimmune diseases

期刊

TRENDS IN MOLECULAR MEDICINE
卷 28, 期 7, 页码 596-612

出版社

CELL PRESS
DOI: 10.1016/j.molmed.2022.04.010

关键词

-

资金

  1. National Natural Science Foundation of China [81788101, 81630044]
  2. CAMS Innovation Fund for Medical Sciences (CIFMS) [2021-I2M-1-017, 2021-I2M-1-047, 2021-I2M-1-040, 2021-I2M-1-016, 2021-I2M-1-026]
  3. National Natural Science Foundation of Beijing [7222263]
  4. Beijing Capital Health Development Fund [2020-2-4019]

向作者/读者索取更多资源

Autoimmune diseases can be treated by restoring immune balance, and low-dose interleukin-2 (IL-2) has immunoregulatory effects on regulatory T cells (T-reg cells). Recent advances have explored the therapeutic potential of IL-2 or IL-2-derived molecules in the treatment of autoimmune diseases.
Autoimmune diseases are characterized by dysregulation and aberrant activation of cells in the immune system. Therefore, restoration of the immune balance represents a promising therapeutic target in autoimmune diseases. Interleukin-2 (IL-2) can promote the expansion and differentiation of different immune cell subsets dose-dependently. At high doses, IL-2 can promote the differentiation and expansion of effector and memory T cells, whereas at low doses, IL-2 can promote the differentiation, survival, and function of regulatory T (T-reg) cells, a CD4(+) T cell subset that is essential for the maintenance of immune homeostasis and immune tolerance. Therefore, IL-2 exerts immunostimulatory and immunosuppressive effects in autoimmune diseases. The immunoregulatory role of low-dose IL-2 has sparked excitement for the therapeutic exploration of modulating the IL-2-Treg axis in the context of autoimmune diseases. In this review, we discuss recent advances in the therapeutic potential of IL-2 or IL-2-derived molecules in the treatment of autoimmune diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据